{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:43:01Z","timestamp":1794663781463,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with\n                    <jats:italic>FLT3<\/jats:italic>\n                    -mutated AML have a high relapse rate and suboptimal outcomes. Many have co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR and those destined to relapse can be identified by high or rising levels of MRD, called molecular failure.\u00a0 This provides a window for pre-emptive intervention, but there is little evidence to guide treatment. The use of\n                    <jats:italic>FLT3<\/jats:italic>\n                    inhibitors (FLT3i) appears attractive but their use has not yet been evaluated. \u00a0We identified 56 patients treated with FLT3i at molecular failure.\u00a0 The\n                    <jats:italic>FLT3<\/jats:italic>\n                    mutation was an ITD in 52, TKD in 7 and both in 3. Over half of patients had previously received midostaurin. Molecular failure occurred at a median 9.2 months from diagnosis and was treated with gilteritinib (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200938), quizartinib (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20097) or sorafenib (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200911). 60% achieved a molecular response, with 45% reaching MRD negativity. Haematological toxicity was low, and 22 patients were bridged directly to allogeneic transplant with another 6 to donor lymphocyte infusion. 2-year overall survival was 80% (95%CI 69\u201393) and molecular event-free survival 56% (95%CI 44\u201372). High-sensitivity next-generation sequencing for\n                    <jats:italic>FLT3<\/jats:italic>\n                    -ITD at molecular failure identified patients more likely to benefit. FLT3i monotherapy for molecular failure is a promising strategy which merits evaluation in prospective studies.\n                  <\/jats:p>","DOI":"10.1038\/s41375-023-01994-x","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T14:02:06Z","timestamp":1691589726000},"page":"2066-2072","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-3576","authenticated-orcid":false,"given":"Jad","family":"Othman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Mokretar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taussig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjum","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramila","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Louise","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cahalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Aries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Belsham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eibhlin","family":"Conneally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-6678","authenticated-orcid":false,"given":"Charles","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Culligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-180X","authenticated-orcid":false,"given":"Sylvie D.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Furness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Gilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Gkreka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-4441","authenticated-orcid":false,"given":"Steven","family":"Knapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Kottaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-0204","authenticated-orcid":false,"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unmesh","family":"Mohite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Ngu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"O\u2019Nions","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-1812","authenticated-orcid":false,"given":"Marianne Tang","family":"Severinsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neill","family":"Storrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-5296","authenticated-orcid":false,"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"1994_CR1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"1994_CR2","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","volume":"111","author":"RE Gale","year":"2008","unstructured":"Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111:2776\u201384.","journal-title":"Blood"},{"key":"1994_CR3","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752\u20139.","journal-title":"Blood"},{"key":"1994_CR4","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","volume":"6","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Weber D, Krzykalla J, Fiedler W, Wulf GG, Salih HR, et al. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv. 2022;6:5345\u201355. bloodadvances.2022007223.","journal-title":"Blood Adv"},{"key":"1994_CR5","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3 -mutated AML. N. Engl J Med. 2019;381:1728\u201340.","journal-title":"N. Engl J Med"},{"key":"1994_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00677-7","volume":"12","author":"AE Perl","year":"2022","unstructured":"Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, et al. Clinical outcomes in patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer J. 2022;12:1\u20139.","journal-title":"Blood Cancer J"},{"key":"1994_CR7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20:984\u201397.","journal-title":"Lancet Oncol"},{"key":"1994_CR8","doi-asserted-by":"publisher","unstructured":"Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, et al. Outcomes in patients with FLT3-mutated relapsed\/refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy. Transplant Cell Ther. 2022; 29:265.e1-265.e10. https:\/\/doi.org\/10.1016\/j.jtct.2022.12.006.","DOI":"10.1016\/j.jtct.2022.12.006"},{"key":"1994_CR9","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2022;40:4048\u201359. JCO.22.00602","journal-title":"J Clin Oncol"},{"key":"1994_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00410-w","volume":"11","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021;11:1\u20136.","journal-title":"Blood Cancer J"},{"key":"1994_CR11","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367.","journal-title":"Blood"},{"key":"1994_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/blood-2009-04-212530","volume":"115","author":"HB Ommen","year":"2010","unstructured":"Ommen HB, Schnittger S, Jovanovic JV, Ommen IB, Hasle H, \u00d8stergaard M, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010;115:198\u2013205.","journal-title":"Blood"},{"key":"1994_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422\u201333.","journal-title":"N Engl J Med"},{"key":"1994_CR14","doi-asserted-by":"publisher","first-page":"E408","DOI":"10.1002\/ajh.26698","volume":"97","author":"NJ Short","year":"2022","unstructured":"Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, et al. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol. 2022;97:E408\u2013E411.","journal-title":"Am J Hematol"},{"key":"1994_CR15","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","volume":"27","author":"D Grimwade","year":"2009","unstructured":"Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27:3650\u20138.","journal-title":"J Clin Oncol"},{"key":"1994_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/bjh.16857","volume":"191","author":"A Bataller","year":"2020","unstructured":"Bataller A, O\u00f1ate G, Diaz-Bey\u00e1 M, Guijarro F, Garrido A, Vives S, et al. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. Br J Haematol. 2020;191:52\u201361.","journal-title":"Br J Haematol"},{"key":"1994_CR17","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19:1668\u201379.","journal-title":"Lancet Oncol"},{"key":"1994_CR18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1182\/blood-2022-163041","volume":"140","author":"IS Tiong","year":"2022","unstructured":"Tiong IS, Hiwase D, Abro EU, Bajel A, Palfreyman E, Loo S, et al. A prospective phase 2 study of Venetoclax and Low Dose Ara-C (VALDAC) to target rising molecular measurable residual disease and early relapse in acute myeloid leukemia. Blood. 2022;140:1453\u20135.","journal-title":"Blood"},{"key":"1994_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273\u201383.","journal-title":"J Clin Oncol"},{"key":"1994_CR20","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood.2019002959","volume":"135","author":"R Dillon","year":"2020","unstructured":"Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, et al. Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood. 2020;135:680\u20138.","journal-title":"Blood"},{"key":"1994_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"1994_CR22","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/blood.2020007626","volume":"137","author":"LK Schmalbrock","year":"2021","unstructured":"Schmalbrock LK, Dolnik A, Cocciardi S, Str\u00e4ng E, Theis F, Jahn N, et al. Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin. Blood. 2021;137:3093\u2013104.","journal-title":"Blood"},{"key":"1994_CR23","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41375-019-0483-z","volume":"33","author":"TJ Bl\u00e4tte","year":"2019","unstructured":"Bl\u00e4tte TJ, Schmalbrock LK, Skambraks S, Lux S, Cocciardi S, Dolnik A, et al. getITD for FLT3-ITD-based MRD monitoring in AML. Leukemia. 2019;33:2535\u20139.","journal-title":"Leukemia"},{"key":"1994_CR24","doi-asserted-by":"crossref","unstructured":"Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, et al. Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia. J Clin Oncol. 2022;41:756\u201365.","DOI":"10.1200\/JCO.22.00715"},{"key":"1994_CR25","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1182\/blood.2022016567","volume":"140","author":"S Loo","year":"2022","unstructured":"Loo S, Dillon R, Ivey A, Anstee NS, Othman J, Tiong IS, et al. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood. 2022;140:2407\u201311.","journal-title":"Blood"},{"key":"1994_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jama.2023.1363","volume":"329","author":"LW Dillon","year":"2023","unstructured":"Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, et al. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA. 2023;329:745\u201355.","journal-title":"JAMA"},{"key":"1994_CR27","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer Program. Leukemia. 2003;17:2318\u201357.","journal-title":"Leukemia"},{"key":"1994_CR28","doi-asserted-by":"publisher","first-page":"9016","DOI":"10.1182\/blood-2022-167097","volume":"140","author":"H Wood","year":"2022","unstructured":"Wood H, Bourlon C, Kulasekararaj A, Borg A, Pavlu J, Elder P, et al. Venetoclax-based non-intensive combinations successfully salvage molecular relapse of acute myeloid leukemia and are an important bridge to cellular therapy in relapsed\/refractory disease\u2014real-world data from a UK-wide programme. Blood. 2022;140:9016\u20138.","journal-title":"Blood"},{"key":"1994_CR29","doi-asserted-by":"publisher","unstructured":"Tiong IS, Dillon R, Ivey A, Teh TC, Nguyen P, Cummings N, et al. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. Br J Haematol. 2020. https:\/\/doi.org\/10.1111\/bjh.16722.","DOI":"10.1111\/bjh.16722"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01994-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01994-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01994-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T13:02:54Z","timestamp":1695906174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01994-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1994"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01994-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742744451.793601212","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JO, NP, KM, DT, PC, JA, MA, EB, EC, DC, MD, CD, SDF, CF, AG, PG, KH, WI, P Kottaridis, MFM, UM, LN, KP, TR, WR, MTS and NS have no conflicts to declare. A Khan declares speakers bureau from Astellas. P Krishnamurthy declares honoraria and speakers bureau from Astellas. ALL declares honoraria from Astella. CC declares consultancy from Astellas and Daiichi-Sankyo. A King declares honoraria from Astellas. SK declares speakers bureau from Astellas. NHR declares honoraria from Astellas. RD declares consultancy with Astellas.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}